Monday, 18 Nov 2019

You are here

Allopurinol Shown to be Renal Protective

Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.

Historically, it has been claimed that allopurinol should be dose-adjusted in patients with renal insufficiency, implying that the drug may lend to renal impairment in susceptible individuals.

Researchers used a UK population for a prospective cohort study of newly diagnosed gout patients initiating allopurinol (≥300 mg/d) compared to those who did not initiate allopurinol. Thus, adults with newly diagnosed gout were propensity matched: 4760 initiators of allopurinol (≥300 mg/d) vs. the same number of noninitiators of allopurinol. Patients with chronic kidney disease stage 3 or higher or prior urate-lowering therapy were excluded.

Patients had a mean follow-up time of 4-5 years, mean age of 57 years, and mean body mass index 30.

Amongst these patients, chronic kidney disease stage 3 or higher was seen in 11.1% of allopurinol initiators and 13.1% of non-users.

Allopurinol (≥300 mg/d) was associated with a 13% lower risk of developing developing chronic kidney disease stage 3 or higher compared with nonusers (hazard ratio (HR) 0.87; 95% CI, 0.77-0.97).  Doses lower than 300 mg/d were not associated with protection against stage >3 CKD (HR, 1.00; 95% CI, 0.91-1.09).

Allopurinol dosed at 300 mg/d or higher was associated with a lower risk of renal function deterioration. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.